Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

The purpose of the study is to study if dose escalated proton radiotherapy can improve local controll for patients with inoperable soft tissue sarcomas. The standard treatment is photon-based radiation. By using proton radiotherapy instead, the hypothesis is that the dose can be increased to enhance treatment effectiveness without increasing side effects. The planned radiation dose is 56 Gy in 16 fractions (treatments) over 4 weeks (4 fractions per week), with a maximum dose escalation centrally in the tumor up to 80 Gy (5 Gy per fraction). At the same time, the study will investigate biomar

Trial Details

NCT ID
NCT07173972
Phase
PHASE2
Sponsor
Oslo University Hospital
Status
RECRUITING
Cancer Type
Liposarcoma Sarcoma
Interventions
  • Definitive radiotherapy
Locations (sample)
  • Bergen, Norway|60.39299,5.32415
  • Oslo, Norway|59.91273,10.74609

Key Eligibility Criteria

  • ≥ 18 years of age at the time of informed consent.
  • Histological diagnosis of soft tissue sarcoma including gastrointestinal stromal tumor (GIST).
  • Measurable disease according to RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liposarcoma Sarcoma Trials on Trialify →